Publication

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

ANNÉE

2024

AUTEURS

Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C

CONGRÈS/REVUE

JAMA Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1001/jamaoncol.2024.0207

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial

ANNÉE

2023

AUTEURS

Salfati D, Huot M, Aparicio T, Lepage C, Taieb J, Bouché O, Boige V, Phelip JM, Dahan L, Bennouna J, Le Malicot K, Boussari O, Gornet JM

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2022.12.018

Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort

ANNÉE

2023

AUTEURS

Lebeaud A, Antoun L, Paccard J, Edeline J, Fares N, Tournigand C, Lecomte T, Tougeron D, Hautefeuille V, Vienot A, Henriques J, Williet N, Bachet JB, Smolenschi C, Hollebecque A, Malka D, Neuzillet C, Vernerey D, Boileve A, Turpin A

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.annonc.2023.09.1413

Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers

ANNÉE

2023

AUTEURS

Pudlarz T, Antoun L, Rousseau A, Nicolle R, Gelli M, Fernandez de Sevilla E, Cosconea S, Tselikas L, Barbe R, Turpin A, Deloger M, Italiano A, Valery M, Tarabay AA, Boige V, Malka D, Smolenschi C, Hollebecque A, Ducreux MP, Boileve A

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.annonc.2023.09.1405

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study

ANNÉE

2023

AUTEURS

Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C

CONGRÈS/REVUE

BMC Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1186/s12885-023-11065-0

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

ANNÉE

2023

AUTEURS

Merle P, Blanc JF, Edeline J, Le Malicot K, Allaire M, Assenat E, Guarssifi M, Bouattour M, Péron JM, Laurent-Puig P, Levrero M, Costentin C, Guiu B, Sokol H, Tougeron D, Aparicio T, Nault JC, Phelip JM.

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2023.01.161

Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study

ANNÉE

2023

AUTEURS

Hammel P, Ben Abdelghani M, Roth G, Ulusakarya A, Ghiringhelli F, Toullec C, Borg C, Hentic Dhome O, Trouilloud I,Dahan L, Hiret S, Bouche O, Rinaldi Y, Blanc JF, De La Fouchardiere C, Neuzillet C, Kamal M, Falcoz A, Turpin A, Guimbaud R

CONGRÈS/REVUE

ASCO

Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study

ANNÉE

2023

AUTEURS

Hammel P, Ben Abdelghani M, Roth G, Ulusakarya A, Ghiringhelli F, Toullec C, Borg C, Hentic Dhome O, Trouilloud I,Dahan L, Hiret S, Bouche O, Rinaldi Y, Blanc JF, De La Fouchardiere C, Neuzillet C, Kamal M, Falcoz A, Turpin A, Guimbaud R

CONGRÈS/REVUE

ASCO GI

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1200/JCO.2024.42.3_suppl.673

PRODIGE 70 – CIRCULATE : Décision de traitement adjuvant dans le cancer du côlon de stade II, basée sur l’analyse de l'ADN tumoral circulant

ANNÉE

2023

AUTEURS

Taïeb J

CONGRÈS/REVUE

JFHOD

Should Cytoreductive Surgery Alone for Peritoneal Metastases of Colorectal Origin be Centralized? A National Study of 4159 Procedures